NPPB and type 2 diabetes mellitus: Our study expanded these findings, and highlighted the utility of NT-proBNP in predicting hard renal endpoints in type 2 diabetes, including incident cases of KF, as well as a 40% drop in eGFR, which has been proposed as a suitable surrogate endpoint for use in clinical trials of renoprotective agents [42].